Sienna Biopharmaceuticals (NASDAQ:SNNA) had its target price lowered by BMO Capital Markets from $27.00 to $17.00 in a report issued on Tuesday, The Fly reports. The brokerage currently has an outperform rating on the stock.
Separately, Cowen set a $45.00 price target on shares of Sienna Biopharmaceuticals and gave the stock a buy rating in a report on Monday, December 3rd.
Shares of NASDAQ SNNA opened at $5.33 on Tuesday. Sienna Biopharmaceuticals has a 1 year low of $5.01 and a 1 year high of $25.71. The company has a quick ratio of 4.86, a current ratio of 4.86 and a debt-to-equity ratio of 0.67.
Sienna Biopharmaceuticals (NASDAQ:SNNA) last announced its quarterly earnings results on Thursday, November 8th. The company reported ($0.82) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.79) by ($0.03). On average, analysts expect that Sienna Biopharmaceuticals will post -2.95 earnings per share for the current fiscal year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its holdings in Sienna Biopharmaceuticals by 11.2% during the third quarter. Vanguard Group Inc. now owns 667,819 shares of the company’s stock worth $9,897,000 after buying an additional 67,240 shares in the last quarter. Morgan Stanley boosted its holdings in Sienna Biopharmaceuticals by 39.1% during the third quarter. Morgan Stanley now owns 544,429 shares of the company’s stock worth $8,068,000 after buying an additional 153,014 shares in the last quarter. Jane Street Group LLC purchased a new stake in Sienna Biopharmaceuticals during the third quarter worth $182,000. Partner Fund Management L.P. boosted its holdings in Sienna Biopharmaceuticals by 1.6% during the third quarter. Partner Fund Management L.P. now owns 1,576,311 shares of the company’s stock worth $23,361,000 after buying an additional 25,018 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Sienna Biopharmaceuticals during the third quarter worth $200,000. 48.18% of the stock is currently owned by hedge funds and other institutional investors.
Sienna Biopharmaceuticals Company Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Recommended Story: Outstanding Shares
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.